Ambroxol Hcl
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
Ambroxol HCl: Repurposing Evaluation — Pending TxGNN Prediction Data
One-Sentence Summary
Ambroxol HCl is a well-established mucolytic and expectorant agent used for respiratory conditions involving abnormal or excessive mucus secretion. This Evidence Pack does not contain TxGNN model prediction results — no new indication target has been identified for evaluation at this time. The overall assessment is currently on Hold, pending completion of the prediction pipeline and supplementation of critical data gaps.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Respiratory diseases with excessive or viscous mucus (e.g., bronchitis, COPD) |
| Predicted New Indication | Not available — TxGNN prediction not yet performed |
| TxGNN Prediction Score | Not available |
| Evidence Level | L5 (no actual studies retrievable; model prediction absent) |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
No TxGNN prediction results are included in this Evidence Pack (predicted_indications is empty). A mechanistic justification for any specific new indication cannot therefore be provided at this stage.
For background context: ambroxol HCl is the active metabolite of bromhexine. It works by stimulating surfactant synthesis in type II pneumocytes, promoting serous secretion in bronchial glands, and enhancing mucociliary clearance — mechanisms that are well-characterised in the management of obstructive and inflammatory airway diseases.
Beyond its classical mucolytic role, published literature has investigated ambroxol as a pharmacological chaperone for glucocerebrosidase (GBA1), giving rise to interest in lysosomal storage disorders and Parkinson’s disease in carriers of GBA1 mutations. There is also preclinical evidence suggesting local anaesthetic and anti-inflammatory properties. These directions represent plausible repurposing hypotheses, but cannot be formally evaluated here without TxGNN scores and a structured evidence package.
Clinical Trial Evidence
Currently no related clinical trials are available in this Evidence Pack.
Literature Evidence
Currently no related literature is available in this Evidence Pack.
Malaysia Market Information
One registration is recorded in the Malaysia (NPRA) database; however, the detailed authorization record was not retrieved in this Evidence Pack.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| — | — | — | Details not retrieved |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This Evidence Pack contains no TxGNN prediction results and no clinical evidence, making it impossible to identify or evaluate a repurposing target. Evaluation cannot proceed until the prediction pipeline is completed and mandatory data gaps are resolved.
To proceed, the following is needed:
- Run TxGNN prediction pipeline for Ambroxol HCl to generate ranked repurposing candidates
- Retrieve NPRA registration details (license number, product name, dosage form, approved indication text) — the current record contains empty fields despite recording 1 licence
- Obtain DrugBank ID and MOA — DrugBank ID is null; querying the DrugBank API is the recommended remediation
- Download and parse the package insert PDF from the Malaysia NPRA portal to populate safety warnings and contraindications (currently blocking further safety screening)
- Re-run evidence collection (ClinicalTrials.gov, PubMed) once a target indication is confirmed from the prediction output
⚠️ This report is for research reference only and does not constitute medical advice. All repurposing candidates require clinical validation before any application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.